I'm struggling to work out which hepatobiliary cancer patients you would actually use this product in. Extra hepatic cholangiocarcinoma is an infiltrative disease, and not particularly mass-forming which I'd have thought you'd need to inject Oncosil into. It is usually managed by stenting and you can use radio frequency ablation. Intrahepatic cholangiocarcinoma is not readily accessible to EUS injection. So, certainly not anything near 50% of patients might be candidates - closer to 1% I'd expect.
News: OSL Oncosil Medical Files For Registration Of Oncosiltm Device In U.S. Market, page-25
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.035(3.48%) |
Mkt cap ! $13.79M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.0¢ | $66.41K | 66.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3907 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 3000 | 1 |
View Market Depth
| Last trade - 15.47pm 23/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |